Manipulating the chemokine system: Therapeutic perspectives for atherosclerosis

Current Opinion in Investigational Drugs

Volumn 11, Issue 3, 2010, Pages 265-272

  Koenen, R R ^a   Weber, C ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Antagonist; Atherosclerosis; Chemokine; Chemokine heteromerization; Inflammation; Mouse model; Therapeutic

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CXCL1 CHEMOKINE; CXCL16 CHEMOKINE; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MARAVIROC; MKEY; MLN 1202; MONOCYTE CHEMOTACTIC PROTEIN 1; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NBI 74330; NR58 3.14.3; RANTES; SB 517785 M; STROMAL CELL DERIVED FACTOR 1ALPHA; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG INHIBITION; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ATHEROSCLEROSIS; CELL MOVEMENT; CHEMOKINES; HUMANS; LEUKOCYTES;

EID: 77649101520     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Hansson GK, Libby P: The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol (2006) 6(7):508-519.
2. Simionescu M: Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol (2007) 27(2):266-274.
3. Tabas I, Williams KJ, Boren J: Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation (2007) 116(16):1832-1844.
4. Galkina E, Ley K: Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol (2009) 27:165-197.
5. Zernecke A, Shagdarsuren E, Weber C: Chemokines in atherosclerosis: An update. Arterioscler Thromb Vasc Biol (2008) 28(11):1897-1908.
6. Weber C, Zernecke A, Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol (2008) 8(10):802-815.
7. Ley K, Laudanna C, Cybulsky MI, Nourshargh S: Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol (2007) 7(9):678-689.
8. Rot A, von Andrian UH: Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells. Annu Rev Immunol (2004) 22:891-928.
9. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE: Regulation of protein function by glycosaminoglycans - As exemplified by chemokines. Annu Rev Biochem (2005) 74: 385-410.
10. Campanella GS, Grimm J, Manice LA, Colvin RA, Medoff BD, Wojtkiewicz GR, Weissleder R, Luster AD: Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity. J Immunol (2006) 177(10):6991-6998.
11. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH: Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA (2003) 100(4):1885-1890.
12. Monteclaro FS, Charo IF: The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1α receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J Biol Chem (1996) 271(32):19084-19092.
13. Blanpain C, Doranz BJ, Bondue A, Govaerts C, De Leener A, Vassart G, Doms RW, Proudfoot A, Parmentier M: The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2003) 278(7): 5179-5187.
14. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA: International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 52(1):145-176.
15. Johnson Z, Schwarz M, Power CA, Wells TN, Proudfoot AE: Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol (2005) 26(5): 268-274.
16. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F: The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem (2005) 280(42):35760-35766.
17. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K et al: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 203(9):2201-2213.
18. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature (1997) 385(6617):640-644.
19. Matloubian M, David A, Engel S, Ryan JE, Cyster JG: A transmembrane CXC chemokine is a ligand for HIVcoreceptor Bonzo. Nat Immunol (2000) 1(4):298-304.
20. Mantovani A: The chemokine system: Redundancy for robust outputs. Immunol Today (1999) 20(6):254-257.
21. Witt DP, Lander AD: Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol (1994) 4(5): 394-400.
22. Weber KS, von Hundelshausen P, Clark-Lewis I, Weber PC, Weber C: Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur J Immunol (1999) 29(2):700-712. (Pubitemid 29078533)
23. Shamri R, Grabovsky V, Gauguet JM, Feigelson S, Manevich E, Kolanus W, Robinson MK, Staunton DE, von Andrian UH, Alon R: Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endotheliumbound chemokines. Nat Immunol (2005) 6(5):497-506.
24. Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K: The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest (2001) 108(9):1307-1314.
25. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (1998) 394(6696): 894-897.
26. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptordeficient mice. Mol Cell (1998) 2(2):275-281.
27. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK: Chemokines in cardiovascular risk prediction. Thromb Haemost (2007) 97(5):748-754.
28. Swirski FK, Weissleder R, Pittet MJ: Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 29(10):1424-1432.
29. Cheng C, Tempel D, van Haperen R, de Boer HC, Segers D, Huisman M, van Zonneveld AJ, Leenen PJ, van der Steen A, Serruys PW, de Crom R et al: Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines. J Clin Invest (2007) 117(3):616-626.
30. Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LK, Terkeltaub RA: Up-regulated expression of the CXCR2 ligand KC/GRO-α in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol (2006) 168(4):1385-1395.
31. Teupser D, Pavlides S, Tan M, Gutierrez-Ramos JC, Kolbeck R, Breslow JL: Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci USA (2004) 101(51): 17795-17800.
32. Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, Charo IF, Mach F: Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation (2005) 112(6):870-878.
33. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z: Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation (2008) 117(13):1649-1657.
34. Saederup N, Chan L, Lira SA, Charo IF: Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: Evidence for independent chemokine functions in atherogenesis. Circulation (2008) 117(13):1642-1648.
35. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F: Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res (2004) 94(2):253-261.
36. Weber C, Weber KS, Klier C, Gu S, Wank R, Horuk R, Nelson PJ: Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(h)1-like/ CD45RO(+) T cells. Blood (2001) 97(4):1144-1146.
37. Baltus T, Weber KS, Johnson Z, Proudfoot AE, Weber C: Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood (2003) 102(6):1985-1988.
38. Kuziel WA, Dawson TC, Quinones M, Garavito E, Chenaux G, Ahuja SS, Reddick RL, Maeda N: CCR5 deficiency is not protective in the early stages of atherogenesis in ApoE knockout mice. Atherosclerosis (2003) 167(1):25-32.
39. Potteaux S, Combadiere C, Esposito B, Lecureuil C, Ait- Oufella H, Merval R, Ardouin P, Tedgui A, Mallat Z: Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol (2006) 26(8):1858-1863.
40. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Mach F et al: CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2007) 27(2):373-379.
41. Potteaux S, Combadiere C, Esposito B, Casanova S, Merval R, Ardouin P, Gao JL, Murphy PM, Tedgui A, Mallat Z: Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice. Mol Med (2005) 11(1-12):16-20.
42. Leonard JT, Roy K: The HIV entry inhibitors revisited. Curr Med Chem (2006) 13(8):911-934.
43. Horuk R: Chemokine receptor antagonists: Overcoming developmental hurdles. Nat Rev Drug Discov (2009) 8(1):23-33.
44. Anders HJ, Frink M, Linde Y, Banas B, Wörnle M, Cohen CD, Vielhauer V, Nelson PJ, Gröne HJ, Schlöndorff D: CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol (2003) 170(11): 5658-5666.
45. Sorensen LN, Paludan SR: Blocking CC chemokine receptor (CCR) 1 and CCR5 during herpes simplex virus type 2 infection in vivo impairs host defence and perturbs the cytokine response. Scand J Immunol (2004) 59(3):321-333.
46. Lutgens E, Faber B, Schapira K, Evelo CT, van Haaften R, Heeneman S, Cleutjens KB, Bijnens AP, Beckers L, Porter JG, Mackay CR et al: Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: Validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation (2005) 111(25):3443-3452.
47. Davidson M, Lekstrom-Himes J, Gilbert J, Donaldson D, Lee Y, Hu M, Xu J: MLN1202, a novel CCR2 antagonist, decreases C-reactive protein in patients at risk for atherosclerotic cardiovascular disease in a double blind placebo controlled study. Circulation (2007) 116(II-171):Abs 874.
48. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL: Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: Cross-talk between MCP-1 and leukotriene B4. J Immunol (1999) 163(11):6148-6154.
49. Serbina NV, Pamer EG: Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol (2006) 7(3): 311-317.
50. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F: A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol (2008) 28(6):1090-1096.
51. Bursill CA, Choudhury RP, Ali Z, Greaves DR, Channon KM: Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation (2004) 110(16):2460-2466.
52. Reckless J, Tatalick L, Wilbert S, McKilligin E, Grainger DJ: Broad-spectrum chemokine inhibition reduces vascular macrophage accumulation and collagenolysis consistent with plaque stabilization in mice. J Vasc Res (2005) 42(6): 492-502.
53. Deruaz M, Frauenschuh A, Alessandri AL, Dias JM, Coelho FM, Russo RC, Ferreira BR, Graham GJ, Shaw JP, Wells TN, Teixeira MM et al: Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med (2008) 205(9):2019-2031.
54. van Wanrooij EJ, Happe H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, Kuiper J: HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2005) 25(12):2642-2647.
55. van Wanrooij EJ, de Jager SC, van Es T, de Vos P, Birch HL, Owen DA, Watson RJ, Biessen EA, Chapman GA, van Berkel TJ, Kuiper J: CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (2008) 28(2):251-257.
56. Nabah YNA, Losada M, Estelles R, Mateo T, Company C, Piqueras L, Lopez-Gines C, Sarau H, Cortijo J, Morcillo EJ, Jose PJ et al: CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration. Arterioscler Thromb Vasc Biol (2007) 27(11):2370-2376.
57. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, Krohn R, Schober A, Sperandio M, Soehnlein O, Bornemann J et al: Protective role of CXC receptor 4/ CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res (2008) 102(2):209-217.
58. Weber C, Koenen RR: Fine-tuning leukocyte responses: Towards a chemokine 'interactome'. Trends Immunol (2006) 27(6):268-273.
59. Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH: Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem (2005) 280(6):4948-4958.
60. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE, Hackeng TM, Weber C: Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood (2005) 105(3): 924-930.
61. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C: RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation (2001) 103(13):1772-1777. (Pubitemid 32291415)
62. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med (2003) 9(1):61-67.
63. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ et al: Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med (2009) 15(1):97-103.
64. Pfizer Inc: Pfizer's Selzentry (maraviroc) tablets, novel treatment for HIV, approved by FDA. Press Release (2007): August 06.
65. Pfizer Inc: Pfizer's Celsentri approved in the European Union, providing a novel treatment option for treatmentexperienced HIV patients. Press Release (2007): September 24.
66. Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Froland SS, Semb AG, Aukrust P: Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol (2003) 41(9):1460-1467.
67. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F et al: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med (2003) 197(11):1537-1549.